营收飙涨461%、现金储备16亿,云顶新耀2024年成功转型Biopharma

动脉网
07 Apr

云顶新耀2024年实现营收7.067亿元,同比增长461%,首次实现年度商业化盈利。公司现金储备达16亿元,毛利率高达83%。核心产品耐赋康®、依嘉®和伊曲莫德商业化布局成功落地,其中耐赋康®贡献了3.53亿元收入,同比激增1581%。依嘉®也保持强劲增长,收入同比增长256%至3.53亿元。公司通过自研与全球权益管线布局,聚焦高价值领域,并在AI+mRNA技术平台持续创新研发,目标是成为亚洲领先...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10